Treatment of Multiple Keratoacanthoma Resistant to Treatment

When keratoacanthoma presents as multiple lesions that have not responded to prior therapeutic efforts, the clinical picture requires a distinct management approach. This protocol addresses exactly this resistant, multiple-lesion scenario.

Clinical Scenario

This protocol applies to patients with multiple keratoacanthomas that are resistant to treatment — a subset that poses particular therapeutic challenges compared with solitary or treatment-responsive lesions.

Treatment Approach

For this resistant, multiple-lesion scenario, a targeted systemic approach has been proposed — specifically involving an epidermal growth factor receptor (EGFR) inhibitor. The specific agent, selection criteria, and full treatment algorithm are detailed in the complete protocol.

Full regimen and clinical guidance available below →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/ijms262010040

Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, has also been proposed for the treatment of resistant, multiple KAs.

View source ↗